These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38334998)

  • 1. Epidemiology and Outcomes of Non-Small Cell Lung Cancer in South Korea.
    Jung HA; Lee DH; Lim SM; Yu H; Yoon S; Kim D; Kim KP; Jeong H; Doh H; Lim S; Kim J; Zhao X; Horsburgh D; Patel D; Kim JA; Toh KC
    JAMA Netw Open; 2024 Feb; 7(2):e2355331. PubMed ID: 38334998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment patterns and survival outcomes for patients with non-small cell lung cancer in the UK in the preimmunology era: a REAL-Oncology database analysis from the I-O Optimise initiative.
    Snee M; Cheeseman S; Thompson M; Riaz M; Sopwith W; Lacoin L; Chaib C; Daumont MJ; Penrod JR; Hall G
    BMJ Open; 2021 Sep; 11(9):e046396. PubMed ID: 34526333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
    Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
    BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
    Saw SPL; Zhou S; Chen J; Lai G; Ang MK; Chua K; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Lim DWT; Tan A; Fong KW; Takano A; Cheng XM; Lim KH; Koh T; Ong BH; Tan EH; Toh CK; Skanderup AJ; Tan SH; Tan DSW
    JAMA Netw Open; 2021 Nov; 4(11):e2131892. PubMed ID: 34739062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012-2018.
    Wolf A; Stratmann JA; Shaid S; Niklas N; Calleja A; Ubhi H; Munro R; Waldenberger D; Carroll R; Daumont MJ; Penrod JR; Lacoin L; Rohde G
    BMC Pulm Med; 2023 Jan; 23(1):16. PubMed ID: 36639770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting.
    Presley CJ; Tang D; Soulos PR; Chiang AC; Longtine JA; Adelson KB; Herbst RS; Zhu W; Nussbaum NC; Sorg RA; Agarwala V; Abernethy AP; Gross CP
    JAMA; 2018 Aug; 320(5):469-477. PubMed ID: 30088010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data.
    Pérol M; Felip E; Dafni U; Polito L; Pal N; Tsourti Z; Ton TGN; Merritt D; Morris S; Stahel R; Peters S
    Ann Oncol; 2022 May; 33(5):511-521. PubMed ID: 35218887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients.
    Wang Z; Zhao J; Ma Z; Cui J; Shu Y; Liu Z; Cheng Y; Leaw SJ; Wu Y; Ma Y; Tan W; Ma X; Zhang Y; Wang J
    Lung Cancer; 2020 Sep; 147():259-268. PubMed ID: 32769013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
    Zhou Q; Song Y; Zhang X; Chen GY; Zhong DS; Yu Z; Yu P; Zhang YP; Chen JH; Hu Y; Feng GS; Song X; Shi Q; Yang LL; Zhang PH; Wu YL
    BMC Cancer; 2017 Jul; 17(1):462. PubMed ID: 28673332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
    Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
    Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
    [No Abstract]   [Full Text] [Related]  

  • 11. Characteristics and outcomes of ALK+ non-small cell lung cancer patients in Korea.
    Lim SH; Yoh KA; Lee JS; Ahn MJ; Kim YJ; Kim SH; Zhang J; Patel D; Swallow E; Kageleiry A; Galebach P; Lee D; Stein K; Degun R; Park K
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e239-e245. PubMed ID: 28419723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study).
    Auliac JB; Monnet I; Dubos-Arvis C; Chiappa AM; Baize N; Bota S; Vergnenegre A; Doubre H; Locher C; Bizieux A; Robinet G; Chouaid C
    Target Oncol; 2017 Dec; 12(6):833-838. PubMed ID: 28762087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.
    Cadranel J; Park K; Arrieta O; Pless M; Bendaly E; Patel D; Sasane M; Nosal A; Swallow E; Galebach P; Kageleiry A; Stein K; Degun R; Zhang J
    Lung Cancer; 2016 Aug; 98():9-14. PubMed ID: 27393500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study.
    Lee DH; Tsao MS; Kambartel KO; Isobe H; Huang MS; Barrios CH; Khattak A; de Marinis F; Kothari S; Arunachalam A; Cao X; Burke T; Valladares A; de Castro J
    PLoS One; 2018; 13(8):e0202865. PubMed ID: 30148862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
    Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
    Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.
    Sakamoto T; Matsubara T; Takahama T; Yokoyama T; Nakamura A; Tokito T; Okamoto T; Akamatsu H; Oki M; Sato Y; Tobino K; Ikeda S; Mori M; Mimura C; Maeno K; Miura S; Harada T; Nishimura K; Hiraoka M; Kenmotsu H; Fujimoto J; Shimokawa M; Yamamoto N; Nakagawa K
    JAMA Netw Open; 2023 Dec; 6(12):e2347700. PubMed ID: 38100106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study.
    de Castro J; Tagliaferri P; de Lima VCC; Ng S; Thomas M; Arunachalam A; Cao X; Kothari S; Burke T; Myeong H; Grattan A; Lee DH
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28748556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
    Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
    JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape.
    Lefebvre AM; Adam J; Nicolazzi C; Larois C; Attenot F; Falda-Buscaiot F; Dib C; Masson N; Ternès N; Bauchet AL; Demers B; Chadjaa M; Sidhu S; Combeau C; Soria JC; Scoazec JY; Naimi S; Angevin E; Chiron M; Henry C
    Lung Cancer; 2023 Oct; 184():107356. PubMed ID: 37660479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in
    He Z; Yang X; Ma T; Yang Q; Zhang C; Chen Y; Wang P; D'Incecco A; Metro G; Uematsu S; Wang Q
    Transl Lung Cancer Res; 2022 Aug; 11(8):1657-1666. PubMed ID: 36090635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.